Gender aspects of CGRP in migraine

被引:90
作者
Labastida-Ramirez, Alejandro [1 ]
Rubio-Beltran, Eloisa [1 ]
Villalon, Carlos M. [2 ]
MaassenVanDenBrink, Antoinette [1 ]
机构
[1] Erasmus MC, Dept Internal Med, Div Vasc Med & Pharmacol, Rotterdam, Netherlands
[2] Cinvestav IPN, Dept Farmacobiol, Unidad Sur, Mexico City, DF, Mexico
关键词
CGRP; estrogen; migraine; ovarian steroid hormones; trigeminovascular system; GENE-RELATED PEPTIDE; DORSAL-ROOT GANGLIA; RANDOMIZED CONTROLLED-TRIAL; FEMALE SEX-HORMONES; RECEPTOR ANTAGONIST TELCAGEPANT; SPINAL TRIGEMINAL NUCLEUS; DERMAL BLOOD-FLOW; CALCITONIN-GENE; MONOCLONAL-ANTIBODY; MESSENGER-RNA;
D O I
10.1177/0333102417739584
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Migraine is two to three times more prevalent in women than in men, but the mechanisms involved in this gender disparity are still poorly understood. In this respect, calcitonin gene-related peptide (CGRP) plays a key role in migraine pathophysiology and, more recently, the functional interactions between ovarian steroid hormones, CGRP and the trigeminovascular system have been recognized and studied in more detail. Aims To provide an overview of CGRP studies that have addressed gender differences utilizing animal and human migraine preclinical research models to highlight how the female trigeminovascular system responds differently in the presence of varying ovarian steroid hormones. Conclusions Gender differences are evident in migraine. Several studies indicate that fluctuations of ovarian steroid hormone (mainly estrogen) levels modulate CGRP in the trigeminovascular system during different reproductive milestones. Such interactions need to be considered when conducting future animal and human experiments, since these differences may contribute to the development of gender-specific therapies.
引用
收藏
页码:435 / 444
页数:10
相关论文
共 50 条
  • [31] CGRP Receptor Antagonism and Migraine Therapy
    Edvinsson, Lars
    Warfvinge, Karin
    CURRENT PROTEIN & PEPTIDE SCIENCE, 2013, 14 (05) : 386 - 392
  • [32] Beyond CGRP: The calcitonin peptide family as targets for migraine and pain
    Rees, Tayla A.
    Hendrikse, Erica R.
    Hay, Debbie L.
    Walker, Christopher S.
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (03) : 381 - 399
  • [33] Dural Immune Cells, CGRP, and Migraine
    Balcziak, Louis K.
    Russo, Andrew F.
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [34] CGRP and migraine: from bench to bedside
    Edvinsson, L.
    REVUE NEUROLOGIQUE, 2021, 177 (07) : 785 - 790
  • [35] Serotonin and CGRP in Migraine
    Aggarwal, Milan
    Puri, Veena
    Puri, Sanjeev
    ANNALS OF NEUROSCIENCES, 2012, 19 (02) : 88 - 94
  • [36] Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success
    Dubowchik, Gene M.
    Conway, Charles M.
    Xin, Alison W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (13) : 6600 - 6623
  • [37] Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives
    De Matteis, Eleonora
    Guglielmetti, Martina
    Ornello, Raffaele
    Spuntarelli, Valerio
    Martelletti, Paolo
    Sacco, Simona
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2020, 20 (06) : 627 - 641
  • [38] Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks
    Alpuente, Alicia
    Gallardo, Victor J.
    Asskour, Laila
    Caronna, Edoardo
    Torres-Ferrus, Marta
    Pozo-Rosich, Patricia
    CEPHALALGIA, 2022, 42 (03) : 186 - 196
  • [39] BDNF and CGRP interaction: Implications in migraine susceptibility
    Lemos, Carolina
    Mendonca, Denisa
    Pereira-Monteiro, Jose
    Barros, Jose
    Sequeiros, Jorge
    Alonso, Isabel
    Sousa, Alda
    CEPHALALGIA, 2010, 30 (11) : 1375 - 1382
  • [40] CGRP Monoclonal Antibodies for Migraine: Rationale and Progress
    Yuan, Hsiangkuo
    Lauritsen, Clinton G.
    Kaiser, Eric A.
    Silberstein, Stephen D.
    BIODRUGS, 2017, 31 (06) : 487 - 501